Foundayo (Orforglipron)

Foundayo (orforglipron) by Eli Lilly is the first FDA-approved non-peptide small-molecule oral GLP-1, approved on April 1, 2026, offering flexible intake with or without food—a critical real-world advantage over oral semaglutide (Wegovy oral), which requires strict fasting. The Phase 3 ATTAIN trial demonstrated a 12.4% average weight loss at 36 mg daily over 72 weeks, with 60% of participants achieving at least 10% reduction. While 12.4% is lower than oral semaglutide's 16.6%, the no-food-restriction dosing likely improves long-term adherence. A standout feature is pricing: $149 per month for self-pay patients, which is dramatically lower than every other GLP-1, with commercially insured patients paying as low as $25 via savings card. Cardiovascular outcomes trials are ongoing, and this affordability could expand GLP-1 access widely.